Theraclone Sciences Secures $1,500,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6048837a-0e37-4642-9023-fe15977f8259&Preview=1 - Date
3/19/2010 - Company Name
Theraclone Sciences - Mailing Address
1124 Columbia Street Seattle Life Sciences Building Seattle, WA 98104 - Company Description
Theraclone Sciences is a Seattle-based, discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies identified using our discovery platform may be uniquely relevant in combating disease and have potential as safe and effective therapeutic agents that could be administered to a broad patient population. - Website
http://www.theraclone-sciences.com - Transaction Type
Venture Equity - Transaction Amount
$1,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Undisclosed
